Mathieu Le Gars Selected Research

Ad26COVS1

1/2022	Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
1/2022	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
1/2022	Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.
10/2021	Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
7/2021	Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.
1/2021	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
1/2021	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mathieu Le Gars Research Topics

Disease

9	COVID-19 01/2022 - 01/2021
3	Infections 01/2022 - 10/2016
1	Weight Loss (Weight Reduction) 01/2022
1	Myalgia 01/2021
1	Fatigue 01/2021
1	Headache (Headaches) 01/2021
1	Pain (Aches) 01/2021
1	Neoplasms (Cancer) 10/2016
1	Autoimmune Diseases (Autoimmune Disease) 10/2016
1	Inflammation (Inflammations) 01/2013

Drug/Important Bio-Agent (IBA)

7	VaccinesIBA 01/2022 - 01/2021
7	Ad26COVS1IBA 01/2022 - 01/2021
1	Neutralizing AntibodiesIBA 01/2022
1	AntibodiesIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Galactosylceramides (Galactocerebrosides)IBA 10/2016
1	Leukocyte Elastase (Neutrophil Elastase)IBA 01/2013

Therapy/Procedure

1	Therapeutics 10/2016